Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,018 recalls, newest first

Class II · Moderate risk

Lorazepam Injection

Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

Terminated Impurity / degradation Hikma Pharmaceuticals USA Inc. NDC 0641-6044-25 D-1307-2022
Class II · Moderate risk

Naftifine Hydrochloride Gel

Failed Impurities/ degradation specifications: Out-of-Specification test results obtained for Unspecified Impurity Relative Retention Time

Terminated Impurity / degradation Tolmar, Inc. NDC 0115-1510-48 D-1300-2022
Class II · Moderate risk

Aripiprazole Tablets

Failed dissolution specifications: OOS for dissolution at the 12-month stability time point.

Terminated Dissolution failure Apotex Corp. NDC 60505-2676-8 D-1285-2022
Class I · High risk

Insulin Glargine

Labeling: Missing label: Label missing from some prefilled pens.

Terminated Labeling / mix-up Mylan Pharmaceuticals Inc NDC 49502-394-71 D-1292-2022

Recalls by year